Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CEO Sells $777,498.26 in Stock

Relay Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Relay Therapeutics CEO Sanjiv Patel sold 48,202 shares for about $777,500, reducing his holdings by 10.23%; he still owned 423,099 shares after the transaction.
  • The sale follows two earlier sales of roughly 48,200 shares each in September and October, at higher average prices of $18.94 and $18.10.
  • Analysts’ consensus rating is “Moderate Buy”, with an average price target of $27; the stock recently traded near $16.11.
  • Five stocks we like better than Relay Therapeutics.

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CEO Sanjiv Patel sold 48,202 shares of the business's stock in a transaction on Thursday, November 19th. The stock was sold at an average price of $16.13, for a total transaction of $777,498.26. Following the completion of the sale, the chief executive officer owned 423,099 shares of the company's stock, valued at $6,824,586.87. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Sanjiv Patel also recently made the following trade(s):

  • On Wednesday, October 7th, Sanjiv Patel sold 48,199 shares of Relay Therapeutics stock. The stock was sold at an average price of $18.10, for a total transaction of $872,401.90.
  • On Tuesday, September 8th, Sanjiv Patel sold 48,199 shares of Relay Therapeutics stock. The stock was sold at an average price of $18.94, for a total transaction of $912,889.06.

Relay Therapeutics Price Performance

NASDAQ:RLAY traded up $0.20 during midday trading on Friday, reaching $16.11. The stock had a trading volume of 3,974,822 shares, compared to its average volume of 3,111,643. Relay Therapeutics, Inc. has a 1-year low of $6.28 and a 1-year high of $21.27. The firm's fifty day simple moving average is $18.18 and its 200-day simple moving average is $15.66. The stock has a market capitalization of $3.56 billion, a P/E ratio of -10.67 and a beta of 1.74.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.03. On average, equities research analysts anticipate that Relay Therapeutics, Inc. will post -1.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Relay Therapeutics

Hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC raised its holdings in Relay Therapeutics by 108.3% in the 3rd quarter. GAMMA Investing LLC now owns 2,850 shares of the company's stock valued at $51,000 after acquiring an additional 1,482 shares in the last quarter. Sanctuary Advisors LLC lifted its position in shares of Relay Therapeutics by 1.1% in the 1st quarter. Sanctuary Advisors LLC now owns 143,816 shares of the company's stock worth $1,431,000 after acquiring an additional 1,588 shares during the period. Eurizon Capital SGR S.p.A. bought a new stake in shares of Relay Therapeutics in the 3rd quarter worth approximately $33,000. Diversified Trust Co grew its holdings in shares of Relay Therapeutics by 2.7% during the 3rd quarter. Diversified Trust Co now owns 67,996 shares of the company's stock worth $1,227,000 after purchasing an additional 1,802 shares in the last quarter. Finally, Allworth Financial LP acquired a new stake in shares of Relay Therapeutics during the 2nd quarter worth approximately $34,000. Institutional investors own 96.98% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on RLAY shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Relay Therapeutics in a research note on Friday, October 2nd. Guggenheim restated a "buy" rating on shares of Relay Therapeutics in a research note on Friday, August 7th. Wall Street Zen upgraded Relay Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, November 7th. Barclays raised their target price on Relay Therapeutics from $27.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Relay Therapeutics in a research report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Relay Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $27.00.

Get Our Latest Analysis on RLAY

About Relay Therapeutics

(Get Free Report)

Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them. Relay's research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3Kα.

Read More

Insider Buying and Selling by Quarter for Relay Therapeutics (NASDAQ:RLAY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Relay Therapeutics Right Now?

Before you consider Relay Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relay Therapeutics wasn't on the list.

While Relay Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines